Table 3 Associations between the three groups of patients and biomarkers: prodromal dementia with Lewy bodies group (pro-DLB), group with one core symptom (1S group), group without any core DLB symptoms (NS group)

ABeta42 abnormal (vs normal)

0.99

[0.36; 2.71]

0.25

[0.04; 1.61]

0.33

T-Tau abnormal (vs normal)

0.36

[0.15; 0.91]

0.40

[0.10; 1.66]

0.067

P-Tau abnormal (vs normal)

0.48

[0.21; 1.08]

0.48

[0.14; 1.64]

0.15

ABeta42/40 abnormal (vs normal)

0.66

[0.25; 1.71]

0.86

[0.20; 3.66]

0.69

Amyloid PET + (vs −)

0.88

[0.40; 1.93]

1.13

[0.36; 3.58]

0.91

Beta^a

[IC95%]

Beta^a

[IC95%]

P-value

Intracranial volume, cm³

− 5.55

[− 22.4;11.28]

− 14.3

[− 35.6; 7.01]

0.41

BPF, %

− 1.11

[− 1.85; − 0.36]

− 0.42

[− 1.36; 0.53]

0.015

Hippocampal volume, mm³

0.02

[− 0.14; 0.17]

− 0.09

[− 0.29; 0.11]

0.61

Mean cortical thickness, mm

− 0.01

[− 0.02; 0.01]

− 0.01

[− 0.03; 0.01]

0.36

ROI cortical thickness ROI, mm

− 0.01

[− 0.03; 0.01]

− 0.02

[− 0.05; 0.01]

0.26

WMH volume, log (mm³)

0.15

[ 0.01; 0.29]

0.11

[− 0.07; 0.29]

0.094

SUVR PET-FDG

0.02

[− 0.02; 0.06]

− 0.02

[− 0.07; 0.03]

0.43

SUVR PET-FDG for disease specific ROI

− 0.00

[− 0.05; 0.04]

− 0.03

[− 0.09; 0.04]

0.68